Lidocaine 10 mg/mL Injection, Solution
Other active recalls for Lidocaine Hydrochloride (different manufacturers) — 6 · tap to view
🆔 Identity & classification
Where does this data come from?
🏷️ RxNorm drug class
This medicine belongs to the Antiarrhythmic class.
Where does this data come from?
🏭 Manufacturer & labeler
Where does this data come from?
🩺 Clinical
- It's best to avoid using two lidocaine products at the same time unless your doctor says it's okay. When you use multiple products containing a local anesthetic, the total amount a...
- Can I use a lidocaine patch and a lidocaine cream at the same time?
- No — please don't do this. Heat significantly increases how much lidocaine is absorbed through your skin, which can push drug levels in your blood higher than they should be. Stick...
- Can I put a heating pad on the area where I applied a lidocaine patch?
Patient education
Supplement & herbal interactions
Where does this data come from?
Ask a licensed pharmacist directly — free, answered by our team.
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
Where does this data come from?
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.138 | $34.45 / 250 ml |
| Medicaid paysCMS SDUD · 12 mo | $5.47 | $1,368.28 / 250 ml |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
| Medicare Part B allowsASP · J2003 | No ASP payment limit on file for J2003 this quarter. | |
Where does this data come from?
🧾 Billing & reimbursement
Where does this data come from?
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Lidocaine Hydrochloride 10 mg/mL 55150-0253-50 | Eugia | 25 vials | $0.054 | AP | Availability likely | save 61% |
| Lidocaine hydrochloride 10 mg/mL 72603-0732-25 | NorthStar | 25 vials | $0.054 | AP | Availability likely | save 61% |
| Lidocaine 10 mg/mL 00143-9577-10 | Hikma | 10 vials | $0.069 | AP | Availability likely | save 50% |
| Lidocaine Hydrochloride 10 mg/mL 00409-4276-01 | Hospira, | 25 vials | $0.069 | AP | Availability likely | save 50% |
| Lidocaine Hydrochloride 10 mg/mL 23155-0940-41 | Heritage | 25 vials | $0.069 | AP | Availability likely | save 50% |
| Lidocaine hydrochloride 10 mg/mL 31722-0116-31 | Camber | 25 vials | $0.069 | AP | Availability likely | save 50% |
| Lidocaine Hydrochloride 10 mg/mL 55150-0252-20 | Eugia | 25 vials | $0.069 | AP | Availability likely | save 50% |
| Lidocaine hydrochloride 10 mg/mL 72603-0722-25 | NorthStar | 25 vials | $0.069 | AP | Availability likely | save 50% |
| Lidocaine Hydrochloride 10 mg/mL 55150-0251-10 | Eugia | 25 vials | $0.138 | AP | Availability likely | — |
| Lidocaine 10 mg/mLthis 63323-0201-10 | Fresenius | 25 vials | $0.138 | AP | Availability likely | — |
| Lidocaine Hydrochloride 10 mg/mL 70756-0645-25 | Lifestar | 25 vials | $0.138 | AP | Availability likely | — |
| Lidocaine 10 mg/mL 00143-9172-10 | Hikma | 10 vials | — | AP | FDA listed | — |
| Lidocaine 10 mg/mL 00143-9578-10 | Hikma | 10 vials | — | AP | FDA listed | — |
| Lidocaine 10 mg/mL 00143-9579-25 | Hikma | 25 vials | — | AP | FDA listed | — |
| Lidocaine Hydrochloride 10 mg/mL 00404-9763-20 | Henry | 1 vial | — | AP | FDA listed | — |
| Lidocaine Hydrochloride 10 mg/mL 00404-9798-50 | Henry | 1 vial | — | AP | FDA listed | — |
| Lidocaine Hydrochloride 10 mg/mL 00404-9888-20 | Henry | 1 vial | — | AP | FDA listed | — |
| Xylocaine 10 mg/mL 00404-9973-20 | Henry | 1 vial | — | AP | FDA listed | — |
| Lidocaine Hydrochloride 10 mg/mL 50090-0258-01 | A-S | 25 vials | — | AP | FDA listed | — |
| 1% Lidocaine Hci 10 mg/mL 51662-1465-01 | HF | 20 ml | — | AP | FDA listed | — |
| 1% Lidocaine Hci 10 mg/mL 51662-1466-01 | HF | 50 ml | — | AP | FDA listed | — |
| XYLOCAIN (LIDOCAINE HCl ) 10 mg/mL 51662-1587-03 | HF | 25 pouches | — | AP | FDA listed | — |
| Xylocaine 20 mg/mL 51662-1590-03 | HF | 25 pouches | — | AP | FDA listed | — |
| Xylocaine 10 mg/mL 51662-1591-03 | HF | 25 pouches | — | AP | FDA listed | — |
| Lidocaine Hydrochloride 10 mg/mL 55154-0124-05 | Cardinal | 5 vials | — | AP | Discontinued | — |
| Lidocaine Hydrochloride 10 mg/mL 55154-8337-05 | Cardinal | 5 vials | — | AP | FDA listed | — |
| Xylocaine 10 mg/mL 63323-0485-26 | Fresenius | 25 vials | — | AP | FDA listed | — |
| Lidocaine Hydrochloride 10 mg/mL 70756-0644-25 | Lifestar | 25 vials | — | AP | FDA listed | — |
| Lidocaine Hydrochloride 10 mg/mL 70756-0646-05 | Lifestar | 5 vials | — | AP | FDA listed | — |
| Lidocaine Hydrochloride 10 mg/mL 70756-0666-10 | Lifestar | 10 vials | — | AP | FDA listed | — |
| Lidocaine Hydrochloride 10 mg/mL 71351-0026-25 | Brookfield | 25 vials | — | AP | FDA listed | — |
| Lidocaine Hydrochloride 10 mg/mL 71872-7137-01 | Medical | 1 vial | — | AP | FDA listed | — |
| Lidocaine 10 mg/mL 71872-7158-01 | Medical | 1 vial | — | AP | FDA listed | — |
| Lidocaine Hydrochloride 10 mg/mL 71872-7184-01 | Medical | 1 vial | — | AP | FDA listed | — |
| Lidocaine Hydrochloride 10 mg/mL 71872-7254-01 | Medical | 1 vial | — | AP | FDA listed | — |
| Lidocaine Hydrochloride 10 mg/mL 71872-7315-01 | Medical | 1 vial | — | AP | FDA listed | — |
| lidocaine hydrochloride 10 mg/mL 71872-7362-01 | Medical | 1 vial | — | AP | FDA listed | — |
| Lidocaine Hydrochloride 10 mg/mL 73293-0004-02 | Huons | 10 vials | — | AP | FDA listed | — |
| lidocaine hydrochloride 10 mg/mL 83634-0651-10 | Avenacy, | 25 vials | — | AP | FDA listed | — |
| Lidocaine Hydrochloride 10 mg/mL 83854-0009-25 | Anthea | 25 vials | — | AP | FDA listed | — |
| Lidocaine Hydrochloride 10 mg/mL 84549-0276-02 | ProPharma | 50 ml | — | AP | FDA listed | — |
| Lidocaine 10 mg/mL 85766-0063-25 | Sportpharm | 25 vials | — | AP | FDA listed | — |
Where does this data come from?
⏳ Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
🗺️ Medicaid utilization & spend
💊 Medicaid utilization by pack size
📊 Medicare Part D spend CMS · PART D · 2026 (Q1)
🔬 Reported adverse events (FAERS)
Top reported reactions
Reporter sex
Where does this data come from?
📦 Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Status |
|---|---|---|---|---|---|
| 63323-0201-10 You're viewing this | 25 VIAL in 1 TRAY (63323-201-10) / 10 mL in 1 VIAL (63323-201-03) | $0.1378 / mL | $34.46 | 2010-05-27 | Active |
| 63323-0201-02 | 25 VIAL in 1 TRAY (63323-201-02) / 2 mL in 1 VIAL (63323-201-01) | — | — | 2010-05-27 | Active |
In Medicaid, this is the most-dispensed pack of this product — about 88% of fills over the last four reported quarters. See all packs ↓
Pack size FAQ
What quantity is in NDC 63323-0201-10?
What NDC number is used to bill for this package of Lidocaine 10 mg/mL Injection, Solution?
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
📄 Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE Lidocaine Hydrochloride Injection, USP is indicated for the production of local anesthesia, by infiltration techniques, such as percutaneous injection, and by peripheral nerve block techniques, such as brachial plexus and inter-costal, when the accepted procedures for these techniques as described in standard textbooks are observed.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION Table 1 (Recommended Dosages) summarizes the recommended volumes and concentrations of lidocaine hydrochloride injection for various types of anesthetic procedures. The dosages suggested in this table are for normal healthy adults and refer to the use of epinephrine-free solutions. When larger volumes are required, only solutions containing epinephrine should be used, except in those cases where vasopressor drugs may be contraindicated.
There have been adverse event reports of chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures. Lidocaine is not approved for this use (see WARNINGS and DOSAGE AND ADMINISTRATION ). These recommended doses serve only as a guide to the amount of anesthetic required for most routine procedures.
The actual volumes and concentrations to be used depend on a number of factors such as type and extent of surgical procedure, depth of anesthesia and degree of muscular relaxation required, duration of anesthesia required and the physical condition of the patient. In all cases the lowest concentration and smallest dose that will produce the desired result should be given. Dosages should be reduced for children and for elderly and debilitated patients and patients with cardiac and/or liver disease.
The onset of anesthesia, the duration of anesthesia and the degree of muscular relaxation are proportional to the volume and concentration (i.e. total dose) of local anesthetic used. Thus, an increase in volume and concentration of lidocaine hydrochloride injection will decrease the onset of anesthesia, prolong the duration of anesthesia, provide a greater degree of muscular relaxation and increase the segmental spread of anesthesia. However, increasing the volume and concentration of lidocaine hydrochloride injection may result in a more profound fall in blood pressure when used in epidural anesthesia.
Although the incidence of side effects with lidocaine is quite low, caution should be exercised when employing large volumes and concentrations, since the incidence of side effects is directly proportional to the total dose of local anesthetic agent injected.
⛔ Contraindications ▾
CONTRAINDICATIONS Lidocaine HCl is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type.
⚠️ Warnings ▾
WARNINGS LIDOCAINE HYDROCHLORIDE INJECTION FOR INFILTRATION AND NERVE BLOCK SHOULD BE EMPLOYED ONLY BY CLINICIANS WHO ARE WELL VERSED IN DIAGNOSIS AND MANAGEMENT OF DOSE-RELATED TOXICITY AND OTHER ACUTE EMERGENCIES THAT MIGHT ARISE FROM THE BLOCK TO BE EMPLOYED AND THEN ONLY AFTER ENSURING THE IMMEDIATE AVAILABILITY OF OXYGEN, OTHER RESUSCITATIVE DRUGS, CARDIOPULMONARY EQUIPMENT AND THE PERSONNEL NEEDED FOR PROPER MANAGEMENT OF TOXIC REACTIONS AND RELATED EMERGENCIES (see also ADVERSE REACTIONS and PRECAUTIONS ). DELAY IN PROPER MANAGEMENT OF DOSE-RELATED TOXICITY, UNDERVENTILATION FROM ANY CAUSE AND/OR ALTERED SENSITIVITY MAY LEAD TO THE DEVELOPMENT OF ACIDOSIS, CARDIAC ARREST AND, POSSIBLY, DEATH.
Intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures is an unapproved use, and there have been post-marketing reports of chondrolysis in patients receiving such infusions. The majority of reported cases of chondrolysis have involved the shoulder joint; cases of gleno-humeral chondrolysis have been described in pediatric and adult patients following intra-articular infusions of local anesthetics with and without epinephrine for periods of 48 to 72 hours. There is insufficient information to determine whether shorter infusion periods are not associated with these findings.
The time of onset of symptoms, such as joint pain, stiffness and loss of motion can be variable, but may begin as early as the 2nd month after surgery. Currently, there is no effective treatment for chondrolysis; patients who experienced chondrolysis have required additional diagnostic and therapeutic procedures and some required arthroplasty or shoulder replacement. To avoid intravascular injection, aspiration should be performed before the local anesthetic solution is injected.
The needle must be repositioned until no return of blood can be elicited by aspiration. Note, however, that the absence of blood in the syringe does not guarantee that intravascular injection has been avoided. Local anesthetic solutions containing antimicrobial preservatives (e.g., methylparaben) should not be used for epidural or spinal anesthesia because the safety of these agents has not been established with regard to intrathecal injection, either intentional or accidental.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Systemic Adverse experiences following the administration of lidocaine HCl are similar in nature to those observed with other amide local anesthetic agents. These adverse experiences are, in general, dose-related and may result from high plasma levels caused by excessive dosage, rapid absorption or inadvertent intravascular injection, or may result from a hypersensitivity, idiosyncrasy or diminished tolerance on the part of the patient.
Serious adverse experiences are generally systemic in nature. The following types are those most commonly reported: Central Nervous System CNS manifestations are excitatory and/or depressant and may be characterized by lightheadedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest. The excitatory manifestations may be very brief or may not occur at all, in which case the first manifestation of toxicity may be drowsiness merging into unconsciousness and respiratory arrest.
Drowsiness following the administration of lidocaine HCl is usually an early sign of a high blood level of the drug and may occur as a consequence of rapid absorption. Cardiovascular System Cardiovascular manifestations are usually depressant and are characterized by bradycardia, hypotension, and cardiovascular collapse, which may lead to cardiac arrest. Allergic Allergic reactions are characterized by cutaneous lesions, urticaria, edema or anaphylactoid reactions.
Allergic reactions may occur as a result of sensitivity either to local anesthetic agents or to the methylparaben used as a preservative in the multiple dose vials. Allergic reactions as a result of sensitivity to lidocaine HCl are extremely rare and, if they occur, should be managed by conventional means. The detection of sensitivity by skin testing is of doubtful value.
Neurologic The incidences of adverse reactions associated with the use of local anesthetics may be related to the total dose of local anesthetic administered and are also dependent upon the particular drug used, the route of administration and the physical status of the patient. In a prospective review of 10,440 patients who received lidocaine HCl for spinal anesthesia, the incidences of adverse reactions were reported to be about 3% each for positional headaches, hypotension and backache; 2% for shivering; and less than 1% each for peripheral nerve symptoms, nausea, respiratory inadequacy and double vision.
Many of these observations may be related to local anesthetic techniques, with or without a contribution from the local anesthetic. There have been reported cases of permanent injury to extraocular muscles requiring surgical repair following retrobulbar administration.
Systemic Adverse experiences following the administration of lidocaine HCl are similar in nature to those observed with other amide local anesthetic agents. These adverse experiences are, in general, dose-related and may result from high plasma levels caused by excessive dosage, rapid absorption or inadvertent intravascular injection, or may result from a hypersensitivity, idiosyncrasy or diminished tolerance on the part of the patient. Serious adverse experiences are generally systemic in nature.
The following types are those most commonly reported:
Central Nervous System CNS manifestations are excitatory and/or depressant and may be characterized by lightheadedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest. The excitatory manifestations may be very brief or may not occur at all, in which…
🆘 Overdosage ▾
OVERDOSAGE Acute emergencies from local anesthetics are generally related to high plasma levels encountered during therapeutic use of local anesthetics or to unintended subarachnoid injection of local anesthetic solution (see ADVERSE REACTIONS , WARNINGS and PRECAUTIONS ). Management of Local Anesthetic Emergencies The first consideration is prevention, best accomplished by careful and constant monitoring of cardiovascular and respiratory vital signs and the patient’s state of consciousness after each local anesthetic injection.
At the first sign of change, oxygen should be administered. The first step in the management of convulsions, as well as underventilation or apnea due to unintended subarachnoid injection of drug solution, consists of immediate attention to the maintenance of a patent airway and assisted or controlled ventilation with oxygen and a delivery system capable of permitting immediate positive airway pressure by mask. Immediately after the institution of these ventilatory measures, the adequacy of the circulation should be evaluated, keeping in mind that drugs used to treat convulsions sometimes depress the circulation when administered intravenously.
Should convulsions persist despite adequate respiratory support, and if the status of the circulation permits, small increments of an ultra-short acting barbiturate (such as thiopental or thiamylal) or a benzodiazepine (such as diazepam) may be administered intravenously. The clinician should be familiar, prior to the use of local anesthetics, with these anticonvulsant drugs. Supportive treatment of circulatory depression may require administration of intravenous fluids and, when appropriate, a vasopressor as directed by the clinical situation (e.g., ephedrine).
If not treated immediately, both convulsions and cardiovascular depression can result in hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest. Underventilation or apnea due to unintentional subarachnoid injection of local anesthetic solution may produce these same signs and also lead to cardiac arrest if ventilatory support is not instituted. If cardiac arrest should occur, standard cardiopulmonary resuscitative measures should be instituted.
Endotracheal intubation, employing drugs and techniques familiar to the clinician, may be indicated, after initial administration of oxygen by mask, if difficulty is encountered in the maintenance of a patent airway or if prolonged ventilatory support (assisted or controlled) is indicated. Dialysis is of negligible value in the treatment of acute overdosage with lidocaine HCl. The oral LD 50 of lidocaine HCl in non-fasted female rats is 459 (346 to 773) mg/kg (as the salt) and 214 (159 to 324) mg/kg (as the salt) in fasted female rats.
Management of Local Anesthetic Emergencies The first consideration is prevention, best accomplished by careful and constant monitoring of cardiovascular and respiratory vital signs and the patient’s state of consciousness after each local anesthetic injection. At the first sign of change, oxygen should be administered. The first step in the management of convulsions, as well as underventilation or apnea due to unintended subarachnoid injection of drug solution, consists of immediate attention to the maintenance of a patent airway and assisted or controlled ventilation with oxygen and a delivery system capable of permitting immediate positive airway pressure by mask.
Immediately after the institution of these ventilatory measures, the adequacy of the circulation should be evaluated, keeping in mind that drugs used to treat convulsions sometimes depress the circulation when administered intravenously. Should convulsions persist despite adequate respiratory support, and if the status of the circulation permits, small increments of an ultra-short acting barbiturate (such as thiopental or thiamylal) or a benzodiazepine (such as diazepam) may be administered intravenously. The clinician should be familiar, prior to the use of loca…
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Mechanism of Action Lidocaine HCl stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. Hemodynamics Excessive blood levels may cause changes in cardiac output, total peripheral resistance, and mean arterial pressure. With central neural blockade these changes may be attributable to block of autonomic fibers, a direct depressant effect of the local anesthetic agent on various components of the cardiovascular system.
The net effect is normally a modest hypotension when the recommended dosages are not exceeded. Pharmacokinetics and Metabolism Information derived from diverse formulations, concentrations and usages reveals that lidocaine HCl is completely absorbed following parenteral administration, its rate of absorption depending, for example, upon various factors such as the site of administration and the presence or absence of a vasoconstrictor agent. Except for intravascular administration, the highest blood levels are obtained following intercostal nerve block and the lowest after subcutaneous administration.
The plasma binding of lidocaine HCl is dependent on drug concentration, and the fraction bound decreases with increasing concentration. At concentrations of 1 to 4 mcg of free base/mL, 60 to 80% of lidocaine HCl is protein bound. Binding is also dependent on the plasma concentration of the alpha-1-acid glycoprotein.
Lidocaine HCl crosses the blood-brain and placental barriers, presumably by passive diffusion. Lidocaine HCl is metabolized rapidly by the liver, and metabolites and unchanged drug are excreted by the kidneys. Biotransformation includes oxidative N-dealkylation, ring hydroxylation, cleavage of the amide linkage, and conjugation.
N-dealkylation, a major pathway of biotransformation, yields the metabolites monoethylglycinexylidide and glycinexylidide. The pharmacological/toxicological actions of these metabolites are similar to, but less potent than, those of lidocaine HCl. Approximately 90% of lidocaine HCl administered is excreted in the form of various metabolites, and less than 10% is excreted unchanged.
The primary metabolite in urine is a conjugate of 4-hydroxy-2,6-dimethylaniline. The elimination half-life of lidocaine HCl following an intravenous bolus injection is typically 1.5 to 2 hours. Because of the rapid rate at which lidocaine HCl is metabolized, any condition that affects liver function may alter lidocaine kinetics.
The half-life may be prolonged two-fold or more in patients with liver dysfunction. Renal dysfunction does not affect lidocaine HCl kinetics but may increase the accumulation of metabolites. Factors such as acidosis and the use of CNS stimulants and depressants affect the CNS levels of lidocaine HCl required to produce overt systemic effects.
Objective adverse manifestations become increasingly apparent with increasing venous plasma levels above 6 mcg free base/mL. In the rhesus monkey arterial blood levels of 18 to 21 mcg/mL have been shown to be threshold for convulsive activity.
Mechanism of Action Lidocaine HCl stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action.
Hemodynamics Excessive blood levels may cause changes in cardiac output, total peripheral resistance, and mean arterial pressure. With central neural blockade these changes may be attributable to block of autonomic fibers, a direct depressant effect of the local anesthetic agent on various components of the cardiovascular system. The net effect is normally a modest hypotension when the recommended dosages are not exceeded.
Pharmacokinetics and Metabolism Information derived from diverse formulations, concentrations and usages reveals that lidocaine HCl is completely absorbed following parenteral administration, its rate of absorption depending, for example, upon various factors…
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Lidocaine Hydrochloride Injection is preserved with 0.1% methylparaben and is available in the following concentrations: Product Code Unit of Sale Strength Each 920102 NDC 63323-201-02 Unit of 25 1% 20 mg per 2 mL (10 mg per mL) NDC 63323-201-01 2 mL Vial 20110 NDC 63323-201-10 Unit of 25 1% 100 mg per 10 mL (10 mg per mL) NDC 63323-201-03 10 mL Multiple Dose Vial 20202 NDC 63323-202-02 Unit of 25 2% 40 mg per 2 mL (20 mg per mL) NDC 63323-202-01 2 mL Vial Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
Protect from light.
📋 Description ▾
DESCRIPTION Lidocaine Hydrochloride Injection, USP is a local anesthetic which is a sterile, nonpyrogenic solution intended for parenteral injection. See INDICATIONS AND USAGE for specific uses. Lidocaine hydrochloride is chemically designated as 2-(Diethylamino) 2’,6’ acetoxylidide monohydrochloride and has the following structural formula: C 14 H 22 N 2 O • HCl M.W.
288.82 Each mL contains: Lidocaine hydrochloride 10 or 20 mg; methylparaben 0.1%; sodium chloride (7 mg and 6 mg of sodium chloride for 1% and 2% respectively) to render it isotonic; Water for Injection q.s. Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment (5.0 to 7.0). structure